Skip to main content
    N

    Nautilus Biotechnology Inc (NAUT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.10
    -0.22 (-9.48%)

    Market Cap: $295.50M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nautilus Biotechnology Inc (NAUT) Earnings: Report Dates and Results

    Updated Oct 27, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Nautilus Biotechnology (NAUT) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Nautilus Biotechnology reported EPS of -$0.12, above the -$0.14 estimate. It beat the EPS estimate in each of the last 11 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    78%(18/23)
    Avg Surprise
    -8.02%
    Streak
    11 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.14
    Range-$0.15 - -$0.11
    6 analysts
    Revenue Consensus
    $267.75K
    Range$196.00K - $315.00K
    6 analysts
    Reports Apr 26, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.12
    Range-$0.14 - -$0.09
    3 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.09-37.0%
    60d ago-$0.09-37.0%
    30d ago-$0.12-7.2%
    7d ago-$0.120.0%
    Current-$0.12
    Revenue Consensus
    $387.50K
    Range$200.00K - $500.00K
    4 analysts

    Next Report

    NAUT has an expected report date of Feb 24, 2027.

    NAUT Earnings Call

    The latest NAUT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, NAUT beat 18, missed 3 and matched 2. The widest gap in the table came in the quarter ended Mar 31, 2021, when EPS landed 337.50% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.12-$0.14-$0.15 - -$0.14+14.29%BeatN/A40 up, 1 downOct 27, 2026$234000
    Jun 30, 2026-$0.11-$0.14-$0.14 - -$0.14+21.43%BeatN/A10 up, 0 downJul 28, 2026$190000
    Mar 31, 2026-$0.12-$0.14-$0.15 - -$0.14+14.29%BeatN/A21 up, 0 downApr 28, 2026N/A
    Dec 31, 2025-$0.11-$0.16N/A+29.03%BeatN/A20 up, 0 downFeb 26, 2026N/A
    Sep 30, 2025-$0.11-$0.15-$0.16 - -$0.14+26.67%BeatN/A22 up, 0 downOct 27, 2025N/A
    Jun 30, 2025-$0.12-$0.14N/A+14.29%BeatN/AN/A0 up, 0 downJul 31, 2025N/A
    Mar 31, 2025-$0.13-$0.14-$0.14 - -$0.13+7.14%BeatN/A33 up, 0 downApr 29, 2025N/A
    Dec 31, 2024-$0.14-$0.15-$0.18 - -$0.15+6.67%BeatN/A31 up, 0 downFeb 26, 2025$9.60M
    Sep 30, 2024-$0.13-$0.17-$0.18 - -$0.15+23.53%BeatN/A40 up, 0 downOct 29, 2024N/A
    Jun 30, 2024-$0.14-$0.16-$0.18 - -$0.15+12.50%BeatN/A50 up, 0 downJul 30, 2024N/A
    Mar 31, 2024-$0.15-$0.16-$0.18 - -$0.14+6.25%BeatN/A40 up, 0 downApr 30, 2024N/A
    Dec 31, 2023-$0.14-$0.14-$0.19 - -$0.120.00%In lineN/A40 up, 0 downFeb 28, 2024$8.21M
    Sep 30, 2023-$0.13-$0.16-$0.18 - -$0.15+18.75%BeatN/A40 up, 0 downOct 31, 2023N/A
    Jun 30, 2023-$0.13-$0.16-$0.17 - -$0.12+18.75%BeatN/A40 up, 0 downAug 2, 2023N/A
    Mar 31, 2023-$0.12-$0.17-$0.18 - -$0.16+29.41%BeatN/A30 up, 0 downMay 2, 2023N/A
    Dec 31, 2022-$0.11-$0.15-$0.17 - -$0.13+26.67%BeatN/A30 up, 0 downFeb 23, 2023N/A
    Sep 30, 2022-$0.11-$0.15-$0.16 - -$0.14+26.67%BeatN/A41 up, 0 downNov 1, 2022N/A
    Jun 30, 2022-$0.12-$0.17-$0.18 - -$0.15+29.41%BeatN/A40 up, 0 downAug 2, 2022N/A
    Mar 31, 2022-$0.13-$0.16-$0.17 - -$0.15+18.75%BeatN/A30 up, 0 downMay 3, 2022N/A
    Dec 31, 2021-$0.13-$0.13-$0.16 - -$0.110.00%In lineN/A40 up, 0 downFeb 24, 2022N/A
    Sep 30, 2021-$0.12-$0.10-$0.11 - -$0.09-20.00%MissN/A20 up, 0 downNov 2, 2021N/A
    Jun 30, 2021-$0.19-$0.07-$0.09 - -$0.05-171.43%MissN/A2N/AAug 10, 2021N/A
    Mar 31, 2021-$0.35-$0.08N/A-337.50%MissN/AN/AN/AJun 10, 2021N/A
    Dec 31, 2020-$0.02N/AN/AN/AN/AN/AN/AN/AMar 30, 2021N/A
    Sep 30, 2020-$0.01N/AN/AN/AN/AN/AN/AN/ANov 13, 2020N/A
    Jun 30, 2020Not reportedN/AN/AN/ANot reportedN/AN/AN/ASep 18, 2020N/A
    Last 26 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.47, after -$0.56 the year before. It was -$0.03 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.47N/A
    Dec 31, 2024-$0.56N/A
    Dec 31, 2023-$0.52N/A
    Dec 31, 2022-$0.47N/A
    Dec 31, 2021-$0.79N/A
    Dec 31, 2020-$0.03N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,400 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,3659
    2026Q2Jun 30, 20266,3277
    2026Q1Mar 31, 20263,6667
    2025Q4Dec 31, 20254,0077
    2025Q3Sep 30, 20252,8906
    2025Q2Jun 30, 20254,9547
    2025Q1Mar 31, 20255,0558
    2024Q4Dec 31, 20244,3819

    2026Q3 Earnings Call

    Opening remarks

    Marissa Moderator Thank you. Earlier today, Nautilus released financial results for the quarter ended September 30, 2026. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investorrelations@nautilus.bio. Joining me today from Nautilus are Sujal Patel, co-founder and CEO, Parag Mallick, co-founder and Chief Scientist, and Anna Mowry, Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast on October 27, 2026. With that, I'll turn the call over to Sujal.

    Sujal Patel Co-founder and CEO Thanks, Marissa, and thank you all for joining us today. Last quarter, I walked you through a deliberate decision to concentrate our resources on proteoforms. This quarter, I want to talk to you about what proteoforms are, why we believe they're one of the most important opportunities in life sciences, and how we're building the foundation for meaningful long-term growth. Let me start with the idea that guides everything we do. We are making functional biology measurable. For decades, proteomics has primarily been about telling us how much protein is present. While the quantity of a protein is meaningful information, it's not the whole story. Most of today's tools don't have the resolution and scale required to measure the myriad of function-driving modifications that vary across every protein molecule. Shotgun mass spectrometry breaks proteins into peptides and infers the proteins from those pieces. Most affinity assays estimate average abundances by measuring a singular epitope on a protein. Either way, functionally distinct protein molecules are undifferentiated, as the information about splice variants, truncations, and which modifications co-occur on the same molecule is lost. That matters because the complexity of human biology does not come from the number of genes we carry. Consider the banana. A banana has almost 40,000 protein-coding genes. As humans, we are clearly more complex than a banana. In the early days of the Human Genome Project, scientists expected humans to have well over 100,000 genes. In fact, we only have about 20,000 genes, half as many as a banana.

    Frequently Asked Questions About NAUT

    When is Nautilus Biotechnology's next earnings date?

    Nautilus Biotechnology's next earnings report is expected for Feb 24, 2027.

    Did NAUT beat earnings estimates last quarter?

    Yes. Nautilus Biotechnology reported EPS of -$0.12 for the quarter ended Sep 30, 2026, above the -$0.14 estimate, a 14.29% surprise.

    What EPS do analysts expect from NAUT next quarter?

    The consensus EPS estimate for Nautilus Biotechnology for the quarter ending Dec 31, 2026 is -$0.14 from 6 analysts, with estimates from -$0.15 to -$0.11.

    How often does NAUT beat earnings estimates?

    Nautilus Biotechnology beat the EPS estimate in each of the last 11 quarters, with an average surprise of +16.01%.